Show simple item record

dc.contributor.authorChilds, A.
dc.contributor.authorZakeri, N.
dc.contributor.authorMa, Y. T.
dc.contributor.authorO'Rourke, J.
dc.contributor.authorRoss, P.
dc.contributor.authorHashem, E.
dc.contributor.authorHubner, Richard A
dc.contributor.authorHockenhull, Kimberley
dc.contributor.authorIwuji, C.
dc.contributor.authorKhan, S.
dc.contributor.authorPalmer, D. H.
dc.contributor.authorConnor, J.
dc.contributor.authorSwinson, D.
dc.contributor.authorDarby, S.
dc.contributor.authorBraconi, C.
dc.contributor.authorRoques, T.
dc.contributor.authorYu, D.
dc.contributor.authorLuong, T. V.
dc.contributor.authorMeyer, T.
dc.date.accessioned2021-09-30T11:56:04Z
dc.date.available2021-09-30T11:56:04Z
dc.date.issued2021en
dc.identifier.citationChilds A, Zakeri N, Ma YT, O’Rourke J, Ross P, Hashem E, et al. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. Br J Cancer. 2021 Sep 15.en
dc.identifier.pmid34526664en
dc.identifier.doi10.1038/s41416-021-01535-2en
dc.identifier.urihttp://hdl.handle.net/10541/624608
dc.description.abstractBackground: Advanced hepatocellular carcinoma (HCC) is commonly diagnosed using non-invasive radiological criteria (NIRC) defined by the European Association for the Study of the Liver or the American Association for the Study of Liver Diseases. In 2017, The National Institute for Clinical Excellence mandated histological confirmation of disease to authorise the use of sorafenib in the UK. Methods: This was a prospective multicentre audit in which patients suitable for sorafenib were identified at multidisciplinary meetings. The primary analysis cohort (PAC) was defined by the presence of Child-Pugh class A liver disease and performance status 0-2. Clinical, radiological and histological data were reported locally and collected on a standardised case report form. Results: Eleven centres reported 418 cases, of which 361 comprised the PAC. Overall, 76% had chronic liver disease and 66% were cirrhotic. The diagnostic imaging was computed tomography in 71%, magnetic resonance imaging in 27% and 2% had both. Pre-existing histology was available in 45 patients and 270 underwent a new biopsy, which confirmed HCC in 93.4%. Alternative histological diagnoses included cholangiocarcinoma (CC) and combined HCC-CC. In cirrhotic patients, NIRC criteria had a sensitivity of 65.4% and a positive predictive value of 91.4% to detect HCC. Two patients (0.7%) experienced mild post-biopsy bleeding. Conclusion: The diagnostic biopsy is safe and feasible for most patients eligible for systemic therapy.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1038/s41416-021-01535-2en
dc.titleBiopsy for advanced hepatocellular carcinoma: results of a multicentre UK auditen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Royal Free London NHS Foundation Trust, London, UKen
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]
refterms.dateFOA2021-10-13T08:28:00Z


Files in this item

Thumbnail
Name:
34526664.pdf
Size:
380.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record